Ronan Abgral

List of Publications by Year in descending order

88	1,976	236925	265206
papers	citations	25	42
		h-index	g-index

96	96	96	2435
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Does ¹⁸F-FDG PET/CT Improve the Detection of Posttreatment Recurrence of Head and Neck Squamous Cell Carcinoma in Patients Negative for Disease on Clinical Follow-up?. Journal of Nuclear Medicine, 2009, 50, 24-29.	5.0	231
2	Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose ActiveÂCardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2018, 11, 94-107.	5.3	152
3	Pretreatment ¹⁸F-FDG PET/CT Radiomics Predict Local Recurrence in Patients Treated with Stereotactic Body Radiotherapy for Early-Stage Nonâ€"Small Cell Lung Cancer: A Multicentric Study. Journal of Nuclear Medicine, 2020, 61, 814-820.	5.0	126
4	Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (â‰¥10%) Well-Differentiated Endocrine Carcinoma Staging. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 665-671.	3.6	93
5	Coronary Artery PET/MR Imaging. JACC: Cardiovascular Imaging, 2017, 10, 1103-1112.	5.3	90
6	Good clinical practice recommendations for the use of PET/CT in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 28-50.	6.4	85
7	Disease Activity in Mitral Annular Calcification. Circulation: Cardiovascular Imaging, 2019, 12, e008513.	2.6	63
8	Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 659-667.	6.4	59
9	18 F-Sodium Fluoride PET/MR for the Assessment of CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2016, 68, 2712-2714.	2.8	59
10	Does ¹⁸fluoroâ€fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical followâ€up?. Head and Neck, 2007, 29, 1115-1120.	2.0	51
11	Clinical Utility of Combined FDG-PET/MR to Assess Myocardial Disease. JACC: Cardiovascular Imaging, 2017, 10, 594-597.	5.3	49
12	V/Q SPECT Interpretation for Pulmonary Embolism Diagnosis: Which Criteria to Use?. Journal of Nuclear Medicine, 2013, 54, 1077-1081.	5.0	41
13	Correction of respiratory and cardiac motion in cardiac PET/MR using MR-based motion modeling. Physics in Medicine and Biology, 2018, 63, 225011.	3.0	36
14	Prognostic value of textural indices extracted from pretherapeutic 18â€F FDGâ€PET/CT in head and neck squamous cell carcinoma. Head and Neck, 2019, 41, 495-502.	2.0	36
15	Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dualâ€phase ¹⁸FDG PETâ€CT imaging in patients with head and neck cancer. Head and Neck, 2016, 38, E600-6.	2.0	35
16	Firstâ€line pembrolizumab for nonâ€"small cell lung cancer patients with PDâ€L1Ââ‰¥50% in a multicenter realâ€life cohort: The PEMBREIZH study. Cancer Medicine, 2020, 9, 2309-2316.	2.8	35
17	Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1957-1964.	6.4	34
18	Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. Nuclear Medicine Communications, 2015, 36, 922-930.	1.1	34

#	Article	IF	Citations
19	Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1839-1847.	6.4	32
20	Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 72-78.	6.4	29
21	Role of SPECT/CT Compared With MRI in the Diagnosis and Management of Patients With Wrist Trauma Occult Fractures. Clinical Nuclear Medicine, 2014, 39, 8-13.	1.3	28
22	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Medicine (United States), 2019, 98, e16417.	1.0	28
23	Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nuclear Medicine Communications, 2010, 31, 766-772.	1.1	27
24	Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nuclear Medicine Communications, 2013, 34, 551-556.	1.1	27
25	Cosmetic Outcome and Chronic Breast Toxicity After Intraoperative Radiation Therapy (IORT) as a Single Modality or as a Boost Using the Intrabeam® Device: A Prospective Study. Annals of Surgical Oncology, 2017, 24, 2547-2555.	1.5	27
26	Prognostic value of fluorine‐18 fluorodeoxyglucose positron‐emission tomography imaging in patients with head and neck squamous cell carcinoma. Head and Neck, 2012, 34, 462-468.	2.0	25
27	Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. Cancer Imaging, 2017, 17, 16.	2.8	24
28	Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer. PLoS ONE, 2019, 14, e0214299.	2.5	23
29	Clinical interest of quantitative bone SPECT-CT in the preoperative assessment of knee osteoarthritis. Medicine (United States), 2018, 97, e11943.	1.0	22
30	A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases. EJNMMI Research, 2018, 8, 14.	2.5	21
31	A transfer learning approach to facilitate ComBat-based harmonization of multicentre radiomic features in new datasets. PLoS ONE, 2021, 16, e0253653.	2.5	21
32	Performance of 18F fluoro-2-déoxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism. Thrombosis Research, 2015, 135, 31-35.	1.7	18
33	Hybrid PET- and MR-driven attenuation correction for enhanced 18F-NaF and 18F-FDG quantification in cardiovascular PET/MR imaging. Journal of Nuclear Cardiology, 2020, 27, 1126-1141.	2.1	17
34	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 1155-1165.	2.0	16
35	Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2021, 46, 111-118.	1.3	14
36	Diagnostic performance of [18]fluorodesoxyglucose positron emission/computed tomography and magnetic resonance imaging in detecting T1‐T2 head and neck squamous cell carcinoma. Laryngoscope, 2018, 128, 378-385.	2.0	13

#	Article	IF	Citations
37	Malignancy rate of focal thyroid incidentaloma detected by FDG PET–CT: results of a prospective cohort study. Endocrine Connections, 2017, 6, 413-421.	1.9	12
38	Clinical perspectives for the use of total body PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1712-1718.	6.4	12
39	Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma. Frontiers in Medicine, 2019, 6, 24.	2.6	11
40	Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ^{68}Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors. Journal of Nuclear Medicine, 2022, 63, 1014-1020.	5.0	11
41	Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. Frontiers in Medicine, 2022, 9, 881551.	2.6	11
42	Assessment of Image Quality and Lesion Detectability With Digital PET/CT System. Frontiers in Medicine, 2021, 8, 629096.	2.6	10
43	Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence. Acta Oncológica, 2018, 57, 375-381.	1.8	9
44	False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians. Frontiers in Medicine, 2018, 5, 275.	2.6	9
45	Feasibility of Systematic Respiratory-Gated Acquisition in Unselected Patients Referred for 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Frontiers in Medicine, 2018, 5, 36.	2.6	8
46	Diagnosis of pulmonary embolism. Nuclear Medicine Communications, 2012, 33, 695-700.	1.1	7
47	Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab. Targeted Oncology, 2017, 12, 505-512.	3.6	7
48	V/Q SPECT for the Assessment of Regional Lung Function: Generation of Normal Mean and Standard Deviation 3-D Maps. Frontiers in Medicine, 2020, 7, 143.	2.6	7
49	Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. Medicine (United) Tj ETQq1 1 0.784314 rgBT /	1.0	7
50	Cystic form of cervical lymphadenopathy. Guidelines of the French Society of Otorhinolaryngology - Head and Neck Surgery (SFORL). Part 1: Diagnostic procedures for lymphadenopathy in case of cervical mass with cystic aspect. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2019, 136, 489-496.	0.7	6
51	Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor. Medicine (United States), 2020, 99, e20021.	1.0	6
52	Integration of 18-FDG PET/CT in the Initial Work-Up to Stage Head and Neck Cancer: Prognostic Significance and Impact on Therapeutic Decision Making. Frontiers in Medicine, 2020, 7, 273.	2.6	6
53	An atypical sarcoidosis involvement in FDG PET/CT. Medicine (United States), 2016, 95, e5700.	1.0	5
54	Assessing the qualitative and quantitative impacts of simple two-class vs multiple tissue-class MR-based attenuation correction for cardiac PET/MR. Journal of Nuclear Cardiology, 2021, 28, 2194-2204.	2.1	5

#	Article	IF	Citations
55	Use of Baseline 18F-FDG PET/CT to Identify Initial Sub-Volumes Associated With Local Failure After Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer. Frontiers in Oncology, 2020, 10, 678.	2.8	5
56	Cystic form of cervical lymphadenopathy in adults. Guidelines of the French Society of Otorhinolaryngology (short version). Part 2â€"etiological diagnosis procedure: Clinical and imaging assessment. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2020, 137, 117-121.	0.7	5
57	Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. Frontiers in Medicine, 2020, 6, 342.	2.6	5
58	Diagnostic value of positron-emission tomography textural indices for malignancy of 18F-fluorodeoxyglucose-avid adrenal lesions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 79-87.	0.7	5
59	Scan-rescan measurement repeatability of 18F-FDG PET/MR imaging of vascular inflammation. Journal of Nuclear Cardiology, 2022, 29, 1660-1670.	2.1	5
60	18F-FDG:18F-NaF PET/MR multi-parametric imaging with kinetics-based bone segmentation for enhanced dual-tracer PET quantification. , 2016, , .		4
61	Retroperitoneal Pelvic Solitary Fibrous Tumor With High Tracer Uptake in 68Ga-DOTATOC PET/CT. Clinical Nuclear Medicine, 2019, 44, e370-e371.	1.3	4
62	Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer. Clinical Nuclear Medicine, 2020, 45, 127-128.	1.3	3
63	Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. Frontiers in Medicine, 2020, 7, 218.	2.6	3
64	Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 444-452.	1.4	3
65	Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors. Scientific Reports, 2021, 11, 4727.	3.3	3
66	Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy. Clinical and Translational Radiation Oncology, 2020, 23, 50-59.	1.7	3
67	Incidental Findings of a Vestibular Schwannoma on 18F-Choline PET/CT. Clinical Nuclear Medicine, 2021, 46, e75-e77.	1.3	3
68	Asymmetric Muscle Activity on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, e336-e337.	1.3	2
69	Clinical Validation of a Pixon-Based Reconstruction Method Allowing a Twofold Reduction in Planar Images Time of 111In-Pentetreotide Somatostatin Receptor Scintigraphy. Frontiers in Medicine, 2017, 4, 143.	2.6	2
70	Direct 4D Patlak 18F-FDG PET/MR for the Multi-Parametric Assessment of active cardiac sarcoidosis. , 2017, , .		2
71	Time trend analysis of pulmonary embolism diagnosis with single-photon emission computed tomography ventilation/perfusion imaging. Nuclear Medicine Communications, 2019, 40, 576-582.	1.1	2
72	Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer. Clinical Nuclear Medicine, 2019, 44, 578-579.	1.3	2

#	Article	IF	Citations
73	Case Report: Nasal Cavity Epithelial-Myoepithelial Carcinoma With High Fluoro-D-Glucose Uptake on Positron Emission Tomography/Computed Tomography. Frontiers in Medicine, 2021, 8, 664520.	2.6	2
74	^{18}F-FDG PET/CTâ€"Based Prognostic Survival Model After Surgery for Head and Neck Cancer. Journal of Nuclear Medicine, 2022, 63, 1378-1385.	5.0	2
75	Early recurrence or submucosal residual of laryngeal squamous cell carcinoma: Diagnosis by CTâ€guided endolaryngeal core biopsy on a transcutaneous approach. Head and Neck, 2013, 35, E202-4.	2.0	1
76	Interest of chest X-ray in tailoring the diagnostic strategy in patients with suspected pulmonary embolism. Blood Coagulation and Fibrinolysis, 2015, 26, 643-648.	1.0	1
77	Review article: FDG-PET in inflammatory diseases. Medecine Nucleaire, 2017, 41, 3-14.	0.2	1
78	Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine, 2018, 43, e310-e311.	1.3	1
79	Scintigraphie pulmonaire pour suspicion dâ€™embolie pulmonaire aiguÃ«Â: Ã©tat des lieux des pratiques en France en 2014. Medecine Nucleaire, 2017, 41, 55-63.	0.2	0
80	An aortic intra mural hematoma in ventilation/perfusion SPECT/CT. Medicine (United States), 2018, 97, e12928.	1.0	0
81	IntÃ©rÃªt complÃ©mentaire de la TEP/TDM au FDG et de lâ€™imagerie conventionnelle dans le bilan initial et le suivi post-thÃ©rapeutique des cancers des VADSÂ: recommandations et perspectives. Medecine Nucleaire, 2018, 42, 422-427.	0.2	0
82	Recommandations et rÃ©fÃ©rentiels. Medecine Nucleaire, 2019, 43, 1-4.	0.2	0
83	Incidental Finding of a Parotid Basal Cell Adenoma With High Tracer Uptake on 68Ga-DOTATOC PET/CT. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, e381-e383.	1.3	0
84	N3 (> 6 cm) squamous cell carcinoma of the head and neck: outcomes and predictive factors in 104 patients. Acta Otorhinolaryngologica Italica, 2021, 41, 221-229.	1.5	0
85	Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer. Frontiers in Medicine, 2021, 8, 691253.	2.6	0
86	Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, .	1.3	0
87	Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. Clinical Nuclear Medicine, 2020, 45, 707-708.	1.3	0
88	Comparison of Volumetric Quantitative PET Parameters Before and After a CT-Based Elastic Deformation on Dual-Time 18FDG-PET/CT Images: A Feasibility Study in a Perspective of Radiotherapy Planning in Head and Neck Cancer. Frontiers in Medicine, 2022, 9, 831457.	2.6	0